Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02947165
Title Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

lung non-small cell carcinoma

clear cell renal cell carcinoma

triple-receptor negative breast cancer

pancreatic cancer

hepatocellular carcinoma

prostate cancer

Advanced Solid Tumor

colorectal cancer


NIS793 + Spartalizumab


Age Groups:
Covered Countries USA | ITA | DEU | CAN | AUT

No variant requirements are available.